drugset / Trial / NCT03762928

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

NCT03762928

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The current study will estimate any inhibitive or inductive effect of PF-06651600 on the pharmacokinetics of midazolam and efavirenz.

Timeline

Start
2018-12-07
Primary completion
2019-01-27
Completion
2019-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified 50 mg Oral
Subject Midazolam Small molecule 2 mg Oral
Subject Ritlecitinib Small molecule 200 mg Oral

Indications

No indication recorded.